Small and large intestinal involvement

Scleroderma: From Pathogenesis to Comprehensive Management

Volumn , Issue , 2012, Pages 485-499

  Clements, Philip J ^a   Getzug, Terri E ^a   Khanna, Dinesh ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anatomic aspects of intestinal involvement; Motility aspects of intestinal involvement; Motility disturbances of small and large; Small and large intestinal involvement

Indexed keywords

EID: 84963715654     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5774-0_41     Document Type: Chapter

References (62)

1. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S15-8.
2. Franck-Larsson K, Graf W, Rönnblom A. Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study. Eur J Gastroenterol Hepatol. 2009;21(2):176-82.
3. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, Mayes MD, Clements PJ, Khanna D. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford). 2010.
4. Thombs BD, Hudson M, Taillefer SS, Baron M. Canadian Scleroderma Research Group. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum. 2008;59(4):504-9.
5. Horswell RR, et al. Scleroderma presenting as the malabsorption syndrome. A case report. Gastroenterology. 1961;40:580.
6. Schuffler MD, et al. Small-intestinal mucosa in pseudoobstruction syndromes. Am J Dig Dis. 1978;23:821.
7. Marguerie C, et al. Malabsorption caused by celiac disease in patients who have scleroderma. Br J Rheumatol. 1995;34:858.
8. Stafford-Brady FJ, et al. Advanced scleroderma bowel: complications and management. J Rheumatol. 1988;15:869.
9. D'Angelo WA, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty eight matched controls. Am J Med. 1969;46:428.
10. Campbell PM, et al. Pathogenesis of systemic sclerosis: a vascular hypothesis. Sem Arthritis Rheum. 1975;4:351.
11. Atkinson M, et al. Oesophageal changes in systemic sclerosis. Gut. 1966;7:402.
12. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158-66.
13. Marie I, Ducrotté P, Denis P, Hellot MF, Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis-a prospective manometric 5-yr follow-up. Rheumatology (Oxford). 2007;46(1):150-3.
14. Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest. 1972;51(10):2663-8.
15. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37(9):1265-82.
16. Eaker EY, Kuldau JG, Verne GN, Ross SO, Sallustio JE. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med. 1999;133(6):551-6.
17. Singh J, Mehendiratta V, Del Galdo F, Jimenez SA, Cohen S, DiMarino AJ, Rattan S. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2009;297(6):G1206-13.
18. Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams Jr RC. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest. 1994;94(2):761-70.
19. Kawaguchi Y, Nakamura Y, Matsumoto I, Nishimagi E, Satoh T, Kuwana M, Sumida T, Hara M. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis. 2009;68:710-4.
20. Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol. 1998;93(7):1085-9.
21. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978-90.
22. Marie I, Levesque H, Ducrotté P, Denis P, Hellot MF, Benichou J, Cailleux N, Courtois H. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96(1):77-83.
23. Gough A, Andrews D, Bacon PA, Emery P. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol. 1995;34(10):976-7.
24. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, Gonvers JJ, Fried M. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54-9.
25. Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302-9.
26. Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol. 1995;34(3):265-9.
27. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002;97(5):1113-26.
28. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443-54.
29. Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297-303.
30. Marie I, Ducrotté P, Denis P, Menard JF, Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009;48(10):1314-9.
31. Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, Savarino E, Indiveri F, Savarino V, Ghio M. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008;103(5):1257-62.
32. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-9.
33. Di Baise JK. Nutritional consequences of small intestine bacterial overgrowth. Prac Gastroenterol. 2008;15-28.
34. Verne GN, Sninsky CA. Chronic intestinal pseudo-obstruction. Dig Dis. 1995;13(3):163-81.
35. Perlemuter G, Cacoub P, Chaussade S, Wechsler B, Couturier D, Piette JC. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum. 1999;42(7):1545-9.
36. Di Ciaula A, Covelli M, Berardino M, Wang DQ, Lapadula G, Palasciano G, Portincasa P. Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. BMC Gastroenterol. 2008;8:7.
37. Gómez-Puerta JA, Gil V, Cervera R, Miquel R, Jiménez S, Ramos-Casals M, Font J. Coeliac disease associated with systemic sclerosis. Ann Rheum Dis. 2004;63(1):104-5.
38. Rosato E, De Nitto D, Rossi C, Libanori V, Donato G, Di Tola M, Pisarri S, Salsano F, Picarelli A. High incidence of celiac disease in patients with systemic sclerosis. J Rheumatol. 2009;36(5):965-9.
39. Wang SJ, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Colonic transit disorders in systemic sclerosis. Clin Rheumatol. 2001;20(4):251-4.
40. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23(6):691-712.
41. Hamel-Roy J, Devroede G, Arhan P, Tétreault L, Duranceau A, Ménard HA. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology. 1985;88(1 Pt 1):1-7.
42. Zbar AP, Aslam M, Gold DM, Gatzen C, Gosling A, Kmiot WA. Parameters of the rectoanal inhibitory reflex in patients with idiopathic fecal incontinence and chronic constipation. Dis Colon Rectum. 1998;41(2):200-8.
43. Massone C, Milone L, Parodi A, Pandolfo N, Rebora A. Anorectal involvement is frequent in limited systemic sclerosis. Acta Derm Venereol. 2002;82(6):446-8.
44. Heyt GJ, Oh MK, Alemzadeh N, Rivera S, Jimenez SA, Rattan S, Cohen S, Dimarino Jr AJ. Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci. 2004;49(6):1040-5.
45. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, Clements PJ, Getzug T, Faithi N, Bechtel A, Furst DE. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Care Res. 2009;81:1257-63.
46. Franck-Larsson K, Hedenström H, Dahl R, Rönnblom A. Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol. 2003;32(6):348-55.
47. Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102(4):837-44.
48. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60(5):422-7.
49. Di Stefano M, Miceli E, Missanelli A, Corazza GR. Treatment of small intestine bacterial overgrowth. Eur Rev Med Pharmacol Sci. 2005;9(4):217-22.
50. Gabrielli M, Sparano L, Roccarina D, Vitale GE, Lauritano EC, Gasbarrini A. Treatment options for small intestinal bacterial overgrowth. Dig Liver Dis Suppl. 2009;3:50-3.
51. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461-7.
52. Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007;13(3):119-23.
53. Ng SC, Clements PJ, Berquist WE, Furst DE, Paulus HE. Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease. Arthritis Rheum. 1989;32(2):212-6.
54. Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician. 2002;65(8):1575-8.
55. Baron M, Bernier P, Côté LF, Delegge MH, Falovitch G, Friedman G, Gornitsky M, Hoffer J, Hudson M, Khanna D, Paterson WG, Schafer D, Toskes PP, Wykes L. Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol. 2010;28(2 Suppl 58):S42-6.
56. Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36(5):386-9.
57. Wang SJ, Lan JL, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY. Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21(4):271-4.
58. Miner PB, Donnelly TC, Read NW. Investigation of mode of action of biofeedback in treatment of fecal incontinence. Dig Dis Sci. 1990;35(10):1291-8.
59. Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002;51(6):881-3.
60. Hetzer FH, Hahnloser D, Clavien PA, Demartines N. Quality of life and morbidity after permanent sacral nerve stimulation for fecal incontinence. Arch Surg. 2007;142(1):8-13.
61. Quiroz ES, Flannery MT, Martinez EJ, Warner EA. Pneumatosis cystoides intestinalis in progressive systemic sclerosis: a case report and literature review. Am J Med Sci. 1995;310(6):252-5.
62. Attar A, Flourié B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowthrelated chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117(4):794-7.